APA (7th ed.) Citation

S, M., W, J., H, I., YH, P., M, V. L., W, L., . . . D, C. (2025). Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature medicine, 31(12), 4205. https://doi.org/10.1038/s41591-025-03981-4

Chicago Style (17th ed.) Citation

S, Modi, et al. "Trastuzumab Deruxtecan in HER2-low Metastatic Breast Cancer: Long-term Survival Analysis of the Randomized, Phase 3 DESTINY-Breast04 Trial." Nature Medicine 31, no. 12 (2025): 4205. https://doi.org/10.1038/s41591-025-03981-4.

MLA (9th ed.) Citation

S, Modi, et al. "Trastuzumab Deruxtecan in HER2-low Metastatic Breast Cancer: Long-term Survival Analysis of the Randomized, Phase 3 DESTINY-Breast04 Trial." Nature Medicine, vol. 31, no. 12, 2025, p. 4205, https://doi.org/10.1038/s41591-025-03981-4.